Moderna, Inc. Common Stock vs. Tarsus Pharmaceuticals, Inc. Common Stock
MRNA
Moderna, Inc. Common Stock
$198.88 +2.08%
VS TARSTarsus Pharmaceuticals, Inc. Common Stock
$74.29 -3.62%
Tarsus Pharmaceuticals, Inc. Common Stock (TARS) comes out ahead, leading on 5 of 8 compared factors.
Size & Scale
| MRNA | TARS | |
|---|---|---|
| Market Cap | $77.78 billion | $3.61 billion |
| Revenue (TTM) | $2.23 billion | $606.33 million |
| Net Income (TTM) | $-3,151,000,000 | $-46,476,000 |
MRNA leads on 2 of 3 size & scale factors.
Valuation
| MRNA | TARS | |
|---|---|---|
| Price / Book | 11.50 | 10.40 |
| Price / Sales | 34.91 | 5.95 |
TARS leads on 2 of 2 valuation factors.
Profitability
| MRNA | TARS | |
|---|---|---|
| Net Margin | -141.43% | -7.67% |
| Return on Equity | -46.61% | -13.40% |
TARS leads on 2 of 2 profitability factors.
Risk & Sentiment
| MRNA | TARS | |
|---|---|---|
| Short Interest | 0.01% | 0.31% |
MRNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: MRNA overview, MRNA financials, TARS overview, TARS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.